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L E T T E R TO TH E ED I TOR
SARS‐CoV‐2 reinfection in a cancer patient with a defective
neutralizing humoral response
To the Editor,
Since August 2020, a series of cases of reinfection by a phylogenetically
distinct variant of SARS‐CoV‐2 have been reported, raising pertinent
questions on the heterogeneity of the natural immune response to SARS‐
CoV‐2 infection that may not uniformly confer protective immunity to all
individuals.1–5 Specifically, reinfection seems more likely to occur in in-
dividuals whose immune system has been weakened by underlying co-
morbidities or therapies.6–8 Here, we report a case of a 52‐year‐old male
patient suffering from transitional cell carcinoma of the renal pelvis and
ureter who was infected at two separate times with two genetically
distant SARS‐CoV‐2 strains, with the reappearance of the first strain four
months after the first infection. The patient's past medical history and
treatments are summarized in Figure S1. On June 23, 2020 (Day 0), he
had a cough and fever and was diagnosed with COVID‐19 by SARS‐CoV‐
2 reverse transcriptase‐polymerase chain reaction (RT‐PCR) assay of a
nasopharyngeal swab specimen (cycle threshold, Ct, values for SARS‐
CoV‐2 E, RdRp, and N genes ranged from 25 to 26) (Figure 1A). Chest
X‐ray did not reveal any abnormality, and his clinical conditions improved
with resolution of cough and fever within 2 weeks. On Days 35 and 36,
two consecutive nasopharyngeal swabs resulted negative for SARS‐CoV‐
2 infection. In the next few months, the patient did not show any re-
spiratory symptoms. However, the deterioration of his cancer condition
leading to urinary tract infection and sepsis required further hospitali-
zation. On Day 110, the patient had a fever caused by an ongoing Es-
cherichia coli‐induced sepsis. RT‐PCR assay of a nasopharyngeal swab
resulted positive again, causing concern for a recurrence of COVID‐19
(Ct values of 34 and 36 for E and N genes, and over 40 for the RdRp
gene). An abdominal computed tomography scan performed on Day 113
showed thrombosis of the inferior vena cava, of the right iliac vein, and of
both femoral veins. On Day 115, the patient died from septic shock and
respiratory failure.
Quantitative SARS‐CoV‐2 viral loads by droplet digital PCR detected
546, 1, and 53 copies/μl on Days 0, 110, and 115 nasopharyngeal swabs,
respectively (Figure 1A). Whole‐genome sequencing and phylogenetic
analysis of RNA from the first two specimens showed that the viral
genome found at Day 0 could be grouped in the Nextstrain clade 20B
and Pangolin lineage B.1.1, while the strain isolated on Day 110 belonged
to the Nextstrain clade 20A and Pangolin lineage B.1 (Figure 1B).
However, when we sequenced the RNA from the third sample harvested
on Day 115, we detected again the Nextstrain clade 20B, suggesting that
the first infection strain had never been cleared completely. With regard
to amino acid changes, by analyzing minority variants in the Day 115
specimen, the mutations R203K and G204R, which distinguish B.1 and
B.1.1 lineages, were the predominant ones until 65% coverage, but below
this cut‐off, we were also able to detect significant levels of the wild‐type
virus (Figure 1C). Furthermore, the D614G variant was always present in
specimens isolated on Days 110 and 115, whereas it was absent, even as
a minority variant, in the specimen harvested on Day 0. No evidence of
recombination events was observed. Phylogenetic analysis was con-
gruent with both persistent infection with B.1.1 strains (specimens from
Days 0 and 115) and reinfection with B.1 strain on Day 110.
The patient's blood was only available on Day 110 and re-
sulted negative for the presence of SARS‐CoV‐2 genome by
droplet digital PCR analysis. Rapid immunochromatographic test
on blood resulted positive for immunoglobulin G (IgG) anti‐SARS‐
CoV‐2 N protein. Very low levels of IgG anti‐SARS‐CoV‐2 spike
protein were found in this sample (1200 AU/ml with the low
threshold < 2.544 AU/ml). In addition, anti‐receptor binding do-
main antibodies were determined by a different enzyme‐linked
immunosorbent assay, which confirmed the presence of very low
reactivity. Consistently, the neutralizing activity performed using
the replication‐competent chimeric VSV expressing the SARS‐
CoV‐2 spike protein (rVSV‐SARS‐CoV‐2‐SΔ21) was very low
when compared to convalescent positive control. The inhibitory
concentration (IC50) of the positive control was 0.0007 while the
patient's serum was a thousand times less potent (IC50 = 0.1) and
barely reached 50% of neutralization at the lowest serum dilu-
tion of 1:10 (Figures 1D and S2).9 The fact that VSV harbors the
D614 form of the spike protein—the same found in the strain
isolated on Day 0—and that the G614 form is reportedly unable
to interfere with the neutralizing titer10 rules out any detection
bias of our approach, indicating that the patient did fail to mount
an appropriate neutralizing humoral response.
Overall, this case highlights the concerning risk of reinfection in
cancer patients who fail to mount an efficient neutralizing humoral
response along with the underlying existence of persistent asymp-
tomatic/undetectable infection.
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F IGURE 1 (A) Timeline of clinical presentations and SARS‐CoV‐2 testing, including viral loads (copies/μl) and the strains found in the study
patient. Timing of relevant clinical events, such as the outcome of diagnostic tests, is shown. (B) Phylogenomic analyses of described SARS‐CoV‐2
strains in the study patient. The tree was constructed by the maximum likelihood method. Clade information as inferred by Nextstrain and
Pangolin nomenclatures is shown. (C) Viral genome classification and amino acid mutations were identified according to Nextclade and Pangolin
among the three specimens harvested on Days 0, 110, and 115. (D) Serum neutralizing assay against rVSV‐SARS‐CoV‐2‐SΔ21 with a sample
harvested at Day 110. Data are representative of two independent experiments performed in duplicate. Error bars represent the standard deviation.
Patient (blue dot), normal human serum (Neg) (black triangle), positive serum=COVID‐19 convalescent serum (Pos) (red square)
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